The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2020 | ZUMA-1 safety management study: early use of steroids helps manage side effects
Marie José Kersten, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses the subsequent cohorts of the ZUMA-1 trial (NCT02348216) specifically designed to ameliorate axicabtagene ciloleucel (axi-cel) side effects and assess the impact of prophylactic regimens or earlier interventions on the rate and severity of cytokine release syndrome (CRS) and neurologic toxicities. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.
